top of page
Frequently Asked Questions
Frequently asked questions
Products
Ordering and Miscellaneous
Cannabidiol (CBD) can be thought of as a distant cousin of THC, the active ingredient in marijuana. CBD, however, is non-intoxicating. CBD is available in a plethora of product formulations ranging from oils to topical lotions.
Key Takeaways:
Cannabidiol (CBD) represents some of the most compelling evidence for the therapeutic potential of medical cannabis.
Its efficacy is notably acknowledged by the FDA with the approval of a CBD-based pharmaceutical, Epidiolex®, which is prescribed for rare childhood epilepsy syndromes.
While side effects can occur, they tend to be related to the dosage. The most prevalent adverse effects experienced by adults include gastrointestinal issues like vomiting and diarrhea, as well as drowsiness.
The question, “Is CBD legal in all 50 states?” does not have a straightforward answer in 2025. While federal law permits hemp-derived CBD with less than 0.3% THC, state laws vary widely, ranging from full legality to strict prohibitions. Consumers and businesses must stay informed about the laws in their specific states to navigate the complex legal landscape of CBD. As of July 2025, these states do not allow the sale of CBD-Idaho, Kansas, Nebraska, South Dakota.
A: No, you will not get high from using CBD products available at CBGenius. Our supplements contain cannabidiol (CBD), a non-psychoactive compound derived from hemp, which does not produce the intoxicating effects associated with THC, the compound responsible for the high in marijuana. All our products comply with legal standards limiting THC content to trace amounts that are insufficient to cause any psychoactive effects.
A: Cannabinoids are the primary chemical compounds produced by the cannabis plant, with over 85 identified to date. The most well-known cannabinoid is THC (tetrahydrocannabinol), which is renowned for its psychoactive and recreational effects. Another prominent cannabinoid is CBD (cannabidiol), which, unlike THC, is non-intoxicating and does not produce a "high."
The cannabis plant doesn’t only produce cannabinoids – it is also known for its terpenes, which are chemicals responsible for the cannabis aroma. Terpenes are universally regarded as safe by authorities such as the FDA. Terpenes are often included in aromatherapies. Some common terpenes found in cannabis are pinene, limonene, and myrcene. There are in total over 140 terpenes that are naturally produced in cannabis.
Cannabichromene (CBC) is a non-psychoactive cannabinoid found in the cannabis plant, meaning it does not produce a “high” like THC. The CBC cannabinoid is one of several cannabinoids, including CBD and THC, that interact with the body’s endocannabinoid system, particularly the CB2 receptor. CBC starts as cannabichromenic acid (CBCA), which converts to its active form during the plant’s growth.
Unlike other cannabinoids, CBC does not bind directly to CB1 receptors in the brain, so it isn’t considered a psychoactive cannabinoid. Instead, it may enhance the effect of cannabichromene by working with other cannabinoids like CBD and boosting the body’s natural endocannabinoid anandamide without causing side effects.
The specific side effects of CBC are still unknown, but it’s likely similar to CBD oil and has been shown to be well-tolerated and safe in a few clinical trials.
Cannabigerol (CBG) is called the “mother of all cannabinoids,” a key component in the production of THC, CBD, and CBC, some of the most well-known chemicals in the plant.
Side effects and safety: CBG is generally well tolerated with minimal side effects, primarily when used in a pure form without THC. Reported side effects are mild and include dry mouth and sleepiness, mainly when THC is present in the product.
Cannabinol (CBN) is a common and weakly-psychoactive cannabinoid that is naturally present in cannabis and hemp plants.
Side effects: CBN is generally well-tolerated and non-impairing with few known side effects, mainly mild and described as enjoyable. Existing studies are outdated, pointing to a need for updated research to clarify any adverse effects.
bottom of page
